Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With CRSwNP

RecruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

June 6, 2024

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2027

Conditions

Chronic Rhinosinusitis With Nasal PolypsChronic Rhinosinusitis Without Nasal Polyps

Interventions

DRUG

Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]

300mg/2 weeks

Trial Locations (1)

RECRUITING

Medical University of Vienna, Vienna

All Listed Sponsors

lead

Medical University of Vienna

OTHER